CT
Cheng-Yu Tsai
Stanford University
Research areas: Medicine · Oncology · PARP inhibition in cancer therapy · Acute Myeloid Leukemia Research · Pancreatitis Pathology and Treatment
Employment
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (32)
- Induction of acute pancreatitis in adult zebrafish: A reproducible and quantifiable experimental model Save
- A lipid-immune network signature defines susceptibility to asparaginase-associated pancreatitis. Save
- Deep characterization of the vitamin A apparatus in healthy pancreas and during pancreatitis using open-source transcriptomics data Save
- Why is the rectal route for NSAIDS favorable for preventing post-ERCP pancreatitis? Save
- Rectal administration of tacrolimus protects against post-ERCP pancreatitis in mice Save
- A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis Save
- Preclinical safety evaluation of calcineurin inhibitors delivered through an intraductal route to prevent post-ERCP pancreatitis demonstrates endocrine and systemic safety Save
- A large-scale proteomic analysis reveals massive serum proteomic flux after induction therapy in leukemic patients and pinpoints lower TRAF3 in cases of asparaginase-associated pancreatitis Save
- The double hit of asparaginase and reduced dietary vitamin A predisposes leukemia patients to pancreatitis Save
- Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer Save
- Vitamin A and association with asparaginase-associated pancreatitis in children with acute lymphocytic leukemia. Save
- Impact of acute lymphoblastic leukemia induction therapy: findings from metabolomics on non-fasted plasma samples from a biorepository. Save
- The role of asparagine synthetase on nutrient metabolism in pancreatic disease Save
- Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations Save
- Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells Save
- Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells Save
- Abstract 2860A: Evolution and characterization of carboplatin resistance at single-cell resolution Save
- Abstract 4840: APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency Save
- Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro Save
- APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency Save